 |
|
 |
Drug Delivery |
|
|
South Africa Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
Publication Date May 2008
Publisher Global Markets Direct
Product Type Report
Pages 276
ISBN Number not applicable
Product Code GMD770
|
|
|
Summary
This report is an essential source for in-depth information and data relating to the South Africa Drug Delivery Devices devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the Drug Delivery Devices in South Africa
Scope
- The report provides drug delivery devices information broken down into detailed categories and segments in South Africa.
- Total revenues, products sold, end users, and average pricing.
- Market shares of all the key competitors.
- Key pipeline products that are set to shape the market, broken down by sector.
- Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
- Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
- Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
- Key mergers and acquisitions, partnerships, private equity investments and IPOs.
- Customer, hospitals and physicians data.
Reasons to buy
- Gain a strong understanding of the drug delivery devices market in South Africa.
- Evaluate and compare the attractiveness of the market in the country.
- Identify growth segments and opportunities in each industry sector within the country.
- Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
- Analyze the competitiveness of the market in the country and identify hotspots.
- Develop strategies based on the latest product, brand, expansion and research and development news in the country.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
- Identify and analyze the strengths and weaknesses of the industry incumbents in the country.
|
Content
- 1 Table Of Contents
- 1 Table Of Contents
- 1.1 List 0f Tables
- 1.2 List 0f Figures
- 2 Introduction
- 2.1 What Is This Report About?
- 2.2 Definitions
- 2.2.1 Drug delivery devices
- 2.2.1.1 Needle-free Injections
- 2.2.1.2 Inhalation Systems
- 2.2.1.3 Infusion Systems
- 3 Healthcare Sector Review
- 3.1 Healthcare Sector Review
- 3.2 Healthcare Expenditure
- 4 Drug Delivery Devices in South Africa
- 4.1 Drug Delivery Devices Overall Revenues (2000-2012)
- 4.2 Drug Delivery Devices Overall Volume (2000-2012)
- 4.3 Drug Delivery Devices Company Shares (2005-2006)
- 5 Inhalation Systems in South Africa
- 5.1 Inhalation Systems Overall Revenues (2000-2012)
- 5.1.1 Metered Dose Inhaler Devices Overall Revenues (2000-2012)
- 5.1.2 Dry Powder Inhaler Devices Overall Revenues (2000-2012)
- 5.2 Inhalation Systems Overall Volume (2000-2012)
- 5.2.1 Metered Dose Inhaler devices Overall Volume (2000-2012)
- 5.2.2 Dry Powder Inhaler Devices Overall Volume (2000-2012)
- 5.3 Inhalation Systems Average Price (2000-2012)
- 5.3.1 Metered Dose Inhaler Devices Average Price (2000-2012)
- 5.3.2 Dry Powder Inhaler Devices Average Price (2000-2012)
- 5.4 Inhalation Systems Distribution Share (2005-2006)
- 5.5 Inhalation Systems Company Share (2005-2006)
- 6 Infusion Systems in South Africa
- 6.1 Infusion Systems Overall Revenues (2000-2012)
- 6.1.1 Infusion Disposable Sets Overall Revenue (2000-2012)
- 6.1.2 Infusion Pumps Overall Revenue (2000-2012)
- 6.1.3 Syringe Pumps Overall Revenues (2000-2012)
- 6.2 Infusion Systems Overall Volume (2000-2012)
- 6.2.1 Infusion Disposable Sets Overall Volume (2000-2012)
- 6.2.2 Infusion Pumps Overall Volume (2000-2012)
- 6.2.3 Syringe Pumps Overall Volume (2000-2012)
- 6.3 Infusion Systems Average Price (2000-2012)
- 6.3.1 Infusion Pumps Average Price (2000-2012)
- 6.3.2 Syringe Pumps Average Price (2000-2012)
- 6.3.3 Infusion Disposable Sets Average Price (2000-2012)
- 6.4 Infusion Systems Distribution Share (2005-2006)
- 6.5 Infusion Systems Company Share (2005-2006)
- 7 AstraZeneca PLC Company Profile
- 7.1 Company Overview
- 7.2 Business Overview
- 7.2.1 Products
- 7.2.2 History
- 7.3 Locations And Subsidiaries
- 7.4 Financial Deals Landscape
- 7.4.1 AstraZeneca Completes $6,900 Million Private Placement
- 7.4.2 AstraZeneca Acquires MedImmune
- 7.4.3 AstraZeneca Acquires Biologics Manufacturing Facility From DSM Biologics
- 7.4.4 AstraZeneca Acquires Arrow Therapeutics
- 7.4.5 AstraZeneca Signs An Agreement With Palatin Technologies
- 7.4.6 AstraZeneca Signs An Agreement With Bristol-Myers Squibb
- 7.4.7 AstraZeneca Signs An Agreement With Cubist Pharmaceuticals
- 7.4.8 AstraZeneca Signs An Agreement With Par Pharmaceutical
- 7.4.9 Schering Signs An Agreement With AstraZeneca
- 7.4.10 AstraZeneca Signs An Agreement With Pozen
- 7.4.11 AstraZeneca Signs An Agreement With Abbott
- 7.4.12 AstraZeneca To Sell Its U.S Anaesthetic and Analgesic Product Portfolio To Abraxis BioScience
- 7.4.13 AstraZeneca Acquires KuDOS Pharmaceuticals
- 7.4.14 AstraZeneca Acquires A Stake In Protherics
- 7.4.15 AstraZeneca Signs An Agreement With Targacept
- 7.4.16 AstraZeneca Signs An Agreement With AtheroGenics
- 7.4.17 AstraZeneca UK Signs An Agreement With Protherics
- 7.4.18 AstraZeneca Signs An Agreement With Bayer Schering Pharma Aktiengesellschaft
- 7.4.19 AstraZeneca Signs An Agreement With Astex Therapeutics
- 7.4.20 AstraZeneca Signs An Agreement With Avanir Pharmaceuticals
- 7.4.21 AstraZeneca And Royal Cosun Sells Joint Venture Advanta To Syngenta
- 7.4.22 AstraZeneca Completes Private Placement Of $750 million
- 7.4.23 AstraZeneca Prices EUR750 Million Private Placement
- 7.4.24 AstraZeneca Prices Sterling Bond GBP350 Million And Euro750 Million Eurobond Private Placement
- 7.5 Recent Developments
- 7.5.1 Feb 22, 2008: AstraZeneca To Appeal Judgment In Alabama Medical Pricing Case
- 7.5.2 Feb 18, 2008: AstraZeneca Appoints Non-Executive Director
- 7.5.3 Dec 12, 2007: AstraZeneca Files Patent Infringement Actions in Response to Crestor ANDAs
- 7.5.4 Sep 28, 2007: AstraZeneca Appoints New CFO
- 7.5.5 Jul 25, 2007: AstraZeneca Appoints New Board Member
- 7.5.6 Jun 06, 2007: AstraZeneca CFO Resigns
- 7.5.7 Feb 22, 2007: AstraZeneca To Invest $120 Miilion For R&D In Macclesfield Site
- 7.5.8 Jan 30, 2007: Philips And Leading Healthcare Companies Join For Major Research And Development
- 7.5.9 Jan 22, 2007: AstraZeneca Makes $100 Million Research Investment In Boston
- 8 3M Company Profile
- 8.1 Company Overview
- 8.2 Business Overview
- 8.2.1 Consumer and Office
- 8.2.1.1 Overview
- 8.2.1.2 Capital Expenditure
- 8.2.1.3 Market View
- 8.2.1.4 Key Strategies
- 8.2.2 Display and Graphics
- 8.2.2.1 Overview
- 8.2.2.2 Financials
- 8.2.2.3 Capital Expenditure
- 8.2.2.4 Market View
- 8.2.2.5 Key Strategies
- 8.2.3 Electro and Communications
- 8.2.3.1 Overview
- 8.2.3.2 Financials
- 8.2.3.3 Capital Expenditure
- 8.2.3.4 Market View
- 8.2.3.5 Key Strategies
- 8.2.4 Health Care
- 8.2.4.1 Overview
- 8.2.4.2 Financials
- 8.2.4.3 Capital Expenditure
- 8.2.4.4 Market View
- 8.2.4.5 Key Strategies
- 8.2.5 Industrial and Transportation
- 8.2.5.1 Overview
- 8.2.5.2 Financials
- 8.2.5.3 Capital Expenditure
- 8.2.5.4 Market View
- 8.2.5.5 Key Strategies
- 8.2.6 Safety, Security and Protection Services
- 8.2.6.1 Overview
- 8.2.6.2 Financials
- 8.2.6.3 Capital Expenditure
- 8.2.6.4 Market View
- 8.2.6.5 Key Strategies
- 8.2.7 Products
- 8.3 Value Chain Analysis
- 8.3.1 Manufacturing
- 8.3.1.1 In House Manufacturing
- 8.3.2 Product Development
- 8.3.2.1 Regulatory Approvals
- 8.3.2.2 Clinical Trials
- 8.3.2.3 Research and Development
- 8.3.3 Sales and Marketing
- 8.3.3.1 Partnerships and Alliances
- 8.3.3.2 Licensing Agreements
- 8.3.3.3 E-distribution
- 8.4 SWOT Analysis
- 8.4.1 3M Company Strengths
- 8.4.1.1 Strong performance of Industrial and Transportation segment
- 8.4.1.2 Focused research and development
- 8.4.1.3 Decentralized operations
- 3M Company Weaknesses
- 8.4.1.4 Increased operating costs in the U.S
- 8.4.1.5 Personal care segment's poor performance
- 3M Company Opportunities
- 8.4.1.6 Expanding global presence
- 8.4.1.7 The liquid crystal display
- 8.4.1.8 Enhancing brand portfolio
- 3M Company Threats
- 8.4.1.9 Foreign currency fluctuations
- 8.4.1.10 Increasing cost of raw materials
- 8.4.1.11 Trend for private labels
- 8.5 Revenue Analysis
- 8.5.1 Revenue by Segment
- 8.5.2 Revenue by Geography
- 8.6 Financial and Operational Review
- 8.6.1 Financial Statements
- 8.6.2 Financial Ratios
- 8.7 Locations And Subsidiaries
- 8.8 Financial Deals Landscape
- 8.8.1 3M Canada Acquires Les Entreprises Solumed
- 8.8.2 3M Acquires Bondo
- 8.8.3 3M Acquires Lingualcare
- 8.8.4 3M Acquires Abzil Industria E Comercio
- 8.8.5 3M Acquires Neo Plast
- 8.8.6 3M Acquires Assets Of DMS Chile
- 8.8.7 3M Acquires Business Of Innovative Paper Technologies
- 8.8.8 3M Acquires Powell
- 8.8.9 Gen-Probe Signs An Agreement With 3M Company
- 8.8.10 3M Acquires Acolyte Biomedica
- 8.8.11 3M Acquires Sealed Air Corp.'S Interest In Polymask Corp
- 8.8.12 3M Sells Its Pharmaceutical Business To Meda AB
- 8.8.13 3M Acquires SoftMed Systems
- 8.8.14 3M Sells its Pharmaceuticals Business to Graceway
- 8.8.15 Gen-Probe Signs An Agreement With 3M
- 8.8.16 3M Sells its Pharmaceutical Operations in the Asia Pacific Region to Ironbridge Capital and Archer Capital
- 8.8.17 3M Acquires Biotrace International
- 8.8.18 Ekahau Secures $16 Million In Additional Funding
- 8.8.19 3M Acquires Brontes Technologies
- 8.8.20 3M acquires Nylonge Corp
- 8.8.21 3M Signs An Agreement With ClozeX Medical
- 8.8.22 3M Acquires OMNII Oral Pharmaceuticals
- 8.8.23 3M Sells Pharmaceutical Operations In The United States To Graceway
- 8.8.24 3M Sells Pharmaceutical Business In Europe To Meda AB
- 8.8.25 3M Sells Pharmaceutical Operations In The Asia Pacific To Ironbridge and Archer Capital
- 8.8.26 3M Acquires Accuspray Application Technologies Inc
- 8.8.27 3M to acquire Rochford Thompson Equipment
- 8.8.28 3M To Acquire Aearo Technologies From Permira
- 8.8.29 Permira To Sell Aearo Technologies To 3M
- 8.9 Recent Developments
- 8.9.1 Mar 31, 2008: HighJump Software Introduces Survey Management Solution for Direct Store Delivery Businesses
- 8.9.2 Mar 24, 2008: Brazil's Companhia de Transmissao de Energia Eletrica Paulista Chooses 3M ACCR for Upgrade of Line Over Parana River in Sao Paulo State
- 8.9.3 Mar 19, 2008: 3M to Headquarter Optical Systems Business in Asia
- 8.9.4 Mar 19, 2008: 3M To Headquarter Optical Systems Business In North Asia
- 8.9.5 Feb 11, 2008: 3M Increases Dividend for the 50th Straight Year
- 8.9.6 Nov 12, 2007: 3M Declares Quarterly Dividend
- 8.9.7 Oct 24, 2007: 3M And Sanyo Settle Suit On Lithium Ion Battery
- 8.9.8 Aug 13, 2007: 3M Declares Quarterly Dividend
- 8.9.9 May 08, 2007: 3M Declares Quarterly Dividend
- 8.9.10 Apr 30, 2007: Gen-Probe And 3M Collaborate To Develop Rapid Molecular Tests
- 9 Baxter International Company Profile
- 9.1 Company Overview
- 9.2 Business Overview
- 9.2.1 BioScience
- 9.2.1.1 Overview
- 9.2.1.2 Financials
- 9.2.1.3 Capital Expenditure
- 9.2.2 Medication Delivery
- 9.2.2.1 Overview
- 9.2.2.2 Financials
- 9.2.2.3 Capital Expenditure
- 9.2.3 Renal
- 9.2.3.1 Overview
- 9.2.3.2 Financials
- 9.2.3.3 Capital Expenditure
- 9.2.4 Products
- 9.2.5 History
- 9.3 Value Chain Analysis
- 9.3.1 Manufacturing
- 9.3.1.1 In House Manufacturing
- 9.3.2 Product Development
- 9.3.2.1 Regulatory Approvals
- 9.3.2.2 Clinical Trials
- 9.3.2.3 Research and Development
- 9.3.3 Sales and Marketing
- 9.3.3.1 Partnerships and Alliances
- 9.4 SWOT Analysis
- 9.4.1 Baxter International Inc. Strengths
- 9.4.1.1 Diversified geographic presence
- 9.4.1.2 Sturdy research and development activities
- 9.4.1.3 Strong financial performance
- 9.4.2 Baxter International Inc. Weaknesses
- 9.4.2.1 High levels of inventory
- 9.4.2.2 Decline in revenues of medication delivery
- 9.4.2.3 Reduced capital expenditure
- 9.4.3 Baxter International Inc. Opportunities
- 9.4.3.1 Co-developing alliances
- 9.4.3.2 Increasing End Stage Renal Disease patients
- 9.4.3.3 FDA approval
- 9.4.4 Baxter International Inc. Threats
- 9.4.4.1 Legal proceedings
- 9.4.4.2 Patent litigation
- 9.4.4.3 Stringent regulations
- 9.5 Revenue Analysis
- 9.5.1 Revenue by Segment
- 9.5.2 Revenue by Geography
- 9.6 Financial and Operational Review
- 9.6.1 Financial Statements
- 9.6.2 Financial Ratios
- 9.7 Locations And Subsidiaries
- 9.8 Financial Deals Landscape
- 9.8.1 Baiyunshan And Baxter Form A Joint Venture In China
- 9.8.2 Baxter Signs Licensing Agreement With Intercytex And Spinal Restoration
- 9.8.3 Baxter Sells Transfusion Therapies Business to Texas Pacific and Maverick Capital
- 9.8.4 B. Braun Acquires Renal Therapy Business Of Baxter
- 9.8.5 Innovata signs a license agreement with Baxter International
- 9.8.6 Kuros Biosurgery Signs An Agreement With Baxter International
- 9.8.7 Gambro Signs An Agreement With Baxter
- 9.8.8 Baxter Healthcare And Gambro Enter Into An Agreement
- 9.8.9 Baxter and Cerus Enter Into Agreement With BioOne for Commercialization Of INTERCEPT Blood System
- 9.8.10 Baxter International And Kaketsuken Enter Into Agreement
- 9.8.11 Baxter To Acquire 40% Stake In Shanghai Baxter From Worldbest Treeful
- 9.9 Recent Developments
- 9.9.1 Jan 24, 2008: Baxter Achieves Record Sales and Earnings for Full-Year 2007
- 9.9.2 Dec 18, 2007: Baxter Elects CFO
- 9.9.3 Nov 13, 2007: Baxter Declares Quarterly Dividend
- 9.9.4 Aug 01, 2007: Baxter Elects New Board Director
- 9.9.5 Jul 31, 2007: Baxter Announces Quarterly Dividend
- 9.9.6 Mar 13, 2007: Baxter Declares Additional Share Repurchase Authorization
- 9.9.7 Feb 13, 2007: Baxter Announces Quarterly Dividend
- 9.9.8 Nov 28, 2006: Baxter Announces Annual Dividend
- 9.9.9 Sep 14, 2006: Baxter Appoints President, Baxter Latin America
- 9.10 Baxter International Inc. Pipeline Products
- 9.10.1 Next-Generation Home Hemodialysis Machine
- 9.10.1.1 Product Overview
- 9.10.1.2 Product Description
- 9.10.1.3 Product Status
- 9.10.1.4 Product Milestone
- 10 GlaxoSmithKline plc Company Profile
- 10.1 Company Overview
- 10.2 Business Overview
- 10.2.1 Products
- 10.2.2 History
- 10.3 Locations And Subsidiaries
- 10.4 Financial Deals Landscape
- 10.4.1 GlaxoSmithKline Acquires CNS
- 10.4.2 Bayer HealthCare Acquires Pritor Business From GlaxoSmithKline
- 10.4.3 CNS To Merge With GlaxoSmithKline
- 10.5 Recent Developments
- 10.5.1 Mar 19, 2008: GSK charitable support valued at GBP282 million in 2007
- 10.5.2 Feb 07, 2008: Full-year results announcement 2007
- 10.5.3 Dec 19, 2007: GlaxoSmithKline And Santaris Enter Global R&D Alliance
- 10.5.4 Dec 10, 2007: GlaxoSmithKline And OncoMed Form Strategic Alliance To Develop Cancer Stem Cell Antibody Therapeutics
- 10.5.5 Dec 07, 2007: GlaxoSmithKline Announces Board And Management Changes
- 11 Novartis AG Company Profile
- 11.1 Company Overview
- 11.2 Business Overview
- 11.2.1 Major Products and Services
- 11.3 Locations And Subsidiaries
- 11.4 Financial Deals Landscape
- 11.4.1 Bayer Schering Pharma Acquires U.S. Biologics Manufacturing Facility From Novartis
- 11.4.2 Novartis To Acquire Majority Stake In Alcon From Nestle
- 11.4.3 Novartis to sell Medical Nutrition business unit to Nestl
- 11.4.4 Nestl to Acquire Novartis Medical Nutrition
- 11.4.5 Novartis to sell its division Gerber Products Company to Nestle
- 12 Regulation System
- 12.1 Medical Equipment Regulation System
- 12.2 Regulation of Electromagnetic Medical Devices
- 12.3 Future Outlook
- 13 Pricing and Reimbursement
- 13.1 Reimbursement
- 13.2 Pricing
- 14 Distribution Structure
- 15 APPENDIX
- 15.1 Global Markets Direct Research Methodology
- 15.2 Coverage
- 15.3 Secondary Research
- 15.4 Primary Research
- 15.5 Models
- 15.6 Forecasts
- 15.7 Expert Panels
- 15.8 Currency Conversion
- 15.9 Contact Us
- 15.10 Disclaimer
- 1.1 List 0f Tables
- Table 1: Drug Delivery Devices, South Africa, Overall Revenues ($ mn), 2000-2012
- Table 2: Drug Delivery Devices, South Africa, Overall Revenues ($ mn), Historic, 2000-2007
- Table 3: Drug Delivery Devices, South Africa, Overall Revenues ($ mn), Forecast, 2007-2012
- Table 4: Drug Delivery Devices, South Africa, Category Revenues ($ mn), 2000-2012
- Table 5: Drug Delivery Devices, South Africa, Category Revenues ($ mn), Historic, 2000-2007
- Table 6: Drug Delivery Devices, South Africa, Category Revenues ($ mn), Forecast, 2007-2012
- Table 7: Drug Delivery Devices, South Africa, Category Volume (Units), 2000-2012
- Table 8: Drug Delivery Devices, South Africa, Category Volume (Units), Historic, 2000-2007
- Table 9: Drug Delivery Devices, South Africa, Category Volume (Units), Forecast, 2007-2012
- Table 10: Drug Delivery Devices, South Africa, Company Share by Revenue ($ mn), 2005-2006
- Table 11: Inhalation Systems, South Africa, Overall Revenues ($ mn, Historic, 2000-2007
- Table 12: Inhalation Systems, South Africa, Overall Revenues ($ mn), Forecast, 2007-2012
- Table 13: Inhalation Systems, South Africa, Revenue by Segment ($ mn), Historic, 2000-2007
- Table 14: Inhalation Systems, South Africa, Revenue by Segment ($ mn), Forecast, 2007-2012
- Table 15: Metered Dose Inhaler Devices, South Africa, Overall Revenues ($ mn), Historic, 2000-2007
- Table 16: Metered Dose Inhaler Devices, South Africa, Overall Revenues ($ mn), Forecast, 2007-2012
- Table 17: Dry Powder Inhaler Devices, South Africa, Overall Revenues ($ mn), Historic, 2000-2007
- Table 18: Dry Powder Inhaler Devices, South Africa, Overall Revenues ($ mn), Forecast, 2007-2012
- Table 19: Inhalation Systems, South Africa, Overall Volume (Units), Historic, 2000-2007
- Table 20: Inhalation Systems, South Africa, Overall Volume (Units), Forecast, 2007-2012
- Table 21: Metered Dose Inhaler Devices, South Africa, Overall Volume (Units), Historic, 2000-2007
- Table 22: Metered Dose Inhaler Devices, South Africa, Overall Volume (Units), Forecast, 2007-2012
- Table 23: Dry Powder Inhaler Devices, South Africa, Overall Volume (Units), Historic, 2000-2007
- Table 24: Dry Powder Inhaler Devices, South Africa, Overall Volume (Units), Forecast, 2007-2012
- Table 25: Metered Dose Inhaler Devices, South Africa, Average Price ($), Historic, 2000-2007
- Table 26: Metered Dose Inhaler Devices, South Africa, Average Price ($), Forecast, 2007-2012
- Table 27: Dry Powder Inhaler Devices, South Africa, Average Price ($), Historic, 2000-2007
- Table 28: Dry Powder Inhaler Devices, South Africa, Average Price ($), Forecast, 2007-2012
- Table 29: Inhalation Systems, South Africa, Distribution Share by Revenue ($ mn), 2005-2006
- Table 30: Inhalation Systems, South Africa, Company Share by Revenue ($ mn), 2005-2006
- Table 31: Infusion Systems, South Africa, Overall Revenues ($ mn), Historic, 2000-2007
- Table 32: Infusion Systems, South Africa, Overall Revenues ($ mn), Forecast, 2007-2012
- Table 33: Infusion Systems, South Africa, Revenue by Segment ($ mn), Historic, 2000-2007
- Table 34: Infusion Systems, South Africa, Revenue by Segment ($ mn), Forecast, 2007-2012
- Table 35: Infusion Disposable Sets, South Africa, Overall Revenues ($ mn), Historic, 2000-2007
- Table 36: Infusion Disposable Sets, South Africa, Overall Revenues ($ mn), Forecast, 2007-2012
- Table 37: Infusion Pumps, South Africa, Overall Revenues ($ mn), Historic, 2000-2007
- Table 38: Infusion Pumps, South Africa, Overall Revenues ($ mn), Forecast, 2007-2012
- Table 39: Syringe Pumps, South Africa, Overall Revenues ($ mn), Historic, 2000-2007
- Table 40: Syringe Pumps, South Africa, Overall Revenues ($ mn), Forecast, 2007-2012
- Table 41: Infusion Systems, South Africa, Overall Volume (Units), Historic, 2000-2007
- Table 42: Infusion Systems, South Africa, Overall Volume (Units), Forecast, 2007-2012
- Table 43: Infusion Disposable Sets, South Africa, Overall Volume (Units), Historic, 2000-2007
- Table 44: Infusion Disposable Sets, South Africa, Overall Volume (Units), Forecast, 2007-2012
- Table 45: Infusion Pumps, South Africa, Overall Volume (Units), Historic, 2000-2007
- Table 46: Infusion Pumps, South Africa, Overall Volume (Units), Forecast, 2007-2012
- Table 47: Syringe Pumps, South Africa, Overall Volume (Units), Historic, 2000-2007
- Table 48: Syringe Pumps, South Africa, Overall Volume (Units), Forecast, 2007-2012
- Table 49: Infusion Pumps, South Africa, Average Price ($), Historic, 2000-2007
- Table 50: Infusion Pumps, South Africa, Average Price ($), Forecast, 2007-2012
- Table 51: Syringe Pumps, South Africa, Average Price ($), Historic, 2000-2007
- Table 52: Syringe Pumps, South Africa, Average Price ($), Forecast, 2007-2012
- Table 53: Infusion Disposable Sets, South Africa, Average Price ($), Historic, 2000-2007
- Table 54: Infusion Disposable Sets, South Africa, Average Price ($), Forecast, 2007-2012
- Table 55: Infusion Systems, South Africa, Distribution Share by Revenue ($ mn), 2005-2006
- Table 56: Infusion Systems, South Africa, Company Share by Revenue ($ mn), 2005-2006
- Table 57: AstraZeneca PLC, Subsidiaries
- Table 58: AstraZeneca PLC, Subsidiaries((Contd..)
- Table 59: 3M Company, SWOT Analysis, 2006
- Table 60: 3M Company, Revenue by Segment, USD Million, 2003-2007
- Table 61: 3M Company, Revenue by Geography, USD Million, 2003-2007
- Table 62: 3M Company, Financial Statements, USD Million, 2003-2007
- Table 63: 3M Company, Financial Ratios, USD Million, 2003-2007
- Table 64: 3M Company, Subsidiaries
- Table 65: Baxter International Inc., SWOT Analysis, 2006
- Table 66: Baxter International Inc., Revenue by Segment, USD Million, 2003-2007
- Table 67: Baxter International Inc., Revenue by Geography, USD Million, 2003-2007
- Table 68: Baxter International Inc., Financial Statements, USD Million, 2003-2007
- Table 69: Baxter International Inc., Financial Ratios, USD Million, 2003-2007
- Table 70: Baxter International Inc., Other Locations
- Table 71: Baxter International Inc., Subsidiaries
- Table 72: GlaxoSmithKline plc, Subsidiaries
- Table 73: Novartis Medical Nutrition, Other Locations
- Table 74: Novartis Medical Nutrition, Other Locations(Contd..)
- Table 75: Currency Conversion from USD to Local Currency at 2007 Constant Rate
- 1.2 List 0f Figures
- Figure 1: Drug Delivery Devices, South Africa, Overall Revenues ($ mn), 2000-2012
- Figure 2: Drug Delivery Devices, South Africa, Overall Revenues ($ mn), Historic, 2000-2007
- Figure 3: Drug Delivery Devices, South Africa, Overall Revenues ($ mn), Forecast, 2007-2012
- Figure 4: Drug Delivery Devices, South Africa, Category Revenues ($ mn), 2000-2012
- Figure 5: Drug Delivery Devices, South Africa, Category Revenues ($ mn), Historic, 2000-2007
- Figure 6: Drug Delivery Devices, South Africa, Category Revenues ($ mn), Forecast, 2007-2012
- Figure 7: Drug Delivery Devices, South Africa, Category Volume (Units), 2000-2012
- Figure 8: Drug Delivery Devices, South Africa, Category Volume (Units), Historic, 2000-2007
- Figure 9: Drug Delivery Devices, South Africa, Category Volume (Units), Forecast, 2007-2012
- Figure 10: Drug Delivery Devices, South Africa, Company Share (%), 2006
- Figure 11: Inhalation Systems, South Africa, Overall Revenues ($ mn), Historic, 2000-2007
- Figure 12: Inhalation Systems, South Africa, Overall Revenues ($ mn), Forecast, 2007-2012
- Figure 13: Inhalation Systems, South Africa, Revenue by Segment ($ mn), Historic, 2000-2007
- Figure 14: Inhalation Systems, South Africa, Revenue by Segment ($ mn), Forecast, 2007-2012
- Figure 15: Metered Dose Inhaler Devices, South Africa, Overall Revenues ($ mn), Historic, 2000-2007
- Figure 16: Metered Dose Inhaler Devices, South Africa, Overall Revenues ($ mn), Forecast, 2007-2012
- Figure 17: Dry Powder Inhaler Devices, South Africa, Overall Revenues ($ mn), Historic, 2000-2007
- Figure 18: Dry Powder Inhaler Devices, South Africa, Overall Revenues ($ mn), Forecast, 2007-2012
- Figure 19: Inhalation Systems, South Africa, Overall Volume (Units), Historic, 2000-2007
- Figure 20: Inhalation Systems, South Africa, Overall Volume (Units), Forecast, 2007-2012
- Figure 21: Metered Dose Inhaler Devices, South Africa, Overall Volume (Units), Historic, 2000-2007
- Figure 22: Metered Dose Inhaler Devices, South Africa, Overall Volume (Units), Forecast, 2007-2012
- Figure 23: Dry Powder Inhaler Devices, South Africa, Overall Volume (Units), Historic, 2000-2007
- Figure 24: Dry Powder Inhaler Devices, South Africa, Overall Volume (Units), Forecast, 2007-2012
- Figure 25: Metered Dose Inhaler Devices, South Africa, Average Price ($), Historic, 2000-2007
- Figure 26: Metered Dose Inhaler Devices, South Africa, Average Price ($), Forecast, 2007-2012
- Figure 27: Dry Powder Inhaler Devices, South Africa, Average Price ($), Historic, 2000-2007
- Figure 28: Dry Powder Inhaler Devices, South Africa, Average Price ($), Forecast, 2007-2012
- Figure 29: Inhalation Systems, South Africa, Distribution Share (%), 2006
- Figure 30: Inhalation Systems, South Africa, Company Share (%), 2006
- Figure 31: Infusion Systems, South Africa, Overall Revenues ($ mn), Historic, 2000-2007
- Figure 32: Infusion Systems, South Africa, Overall Revenues ($ mn), Forecast, 2007-2012
- Figure 33: Infusion Systems, South Africa, Revenue by Segment ($ mn), Historic, 2000-2007
- Figure 34: Infusion Systems, South Africa, Revenue by Segment ($ mn), Forecast, 2007-2012
- Figure 35: Infusion Disposable Sets, South Africa, Overall Revenues ($ mn), Historic, 2000-2007
- Figure 36: Infusion Disposable Sets, South Africa, Overall Revenues ($ mn), Forecast, 2007-2012
- Figure 37: Infusion Pumps, South Africa, Overall Revenues ($ mn), Historic, 2000-2007
- Figure 38: Infusion Pumps, South Africa, Overall Revenues ($ mn), Forecast, 2007-2012
- Figure 39: Syringe Pumps, South Africa, Overall Revenues ($ mn), Historic, 2000-2007
- Figure 40: Syringe Pumps, South Africa, Overall Revenues ($ mn), Forecast, 2007-2012
- Figure 41: Infusion Disposable Sets, South Africa, Overall Volume (Units), Historic, 2000-2007
- Figure 42: Infusion Disposable Sets, South Africa, Overall Volume (Units), Forecast, 2007-2012
- Figure 43: Infusion Pumps, South Africa, Overall Volume (Units), Historic, 2000-2007
- Figure 44: Infusion Pumps, South Africa, Overall Volume (Units), Forecast, 2007-2012
- Figure 45: Syringe Pumps, South Africa, Overall Volume (Units), Historic, 2000-2007
- Figure 46: Syringe Pumps, South Africa, Overall Volume (Units), Forecast, 2007-2012
- Figure 47: Infusion Pumps, South Africa, Average Price ($), Historic, 2000-2007
- Figure 48: Infusion Pumps, South Africa, Average Price ($), Forecast, 2007-2012
- Figure 49: Syringe Pumps, South Africa, Average Price ($), Historic, 2000-2007
- Figure 50: Syringe Pumps, South Africa, Average Price ($), Forecast, 2007-2012
- Figure 51: Infusion Disposable Sets, South Africa, Average Price ($), Historic, 2000-2007
- Figure 52: Infusion Disposable Sets, South Africa, Average Price ($), Forecast, 2007-2012
- Figure 53: Infusion Systems, South Africa, Distribution Share (%), 2006
- Figure 54: Infusion Systems, South Africa, Company Share (%), 2006
- Figure 55: 3M Company, Value Chain Analysis
- Figure 56: Baxter International Inc., Value Chain Analysis
- Figure 57: Global Markets Direct Methodology
|
|
|
